Cart
sales@molnova.com
RAF265
CAS No. 927880-90-8
RAF265( CHIR-265 | RAF 265 | RAF-265 | CHIR265 )
Catalog No. M16644 CAS No. 927880-90-8
A potent, oral, dual Raf/VEGFR-2 inhibitor with IC50 of 3-60 nM for C-Raf/B-Raf/B-Raf V600E, EC50 of 30 nM for VEGFR2 phosphorylation.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 96 | In Stock |
|
| 2MG | 54 | In Stock |
|
| 5MG | 85 | In Stock |
|
| 10MG | 143 | In Stock |
|
| 25MG | 266 | In Stock |
|
| 50MG | 426 | In Stock |
|
| 100MG | 626 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRAF265
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, oral, dual Raf/VEGFR-2 inhibitor with IC50 of 3-60 nM for C-Raf/B-Raf/B-Raf V600E, EC50 of 30 nM for VEGFR2 phosphorylation.
-
DescriptionA potent, oral, dual Raf/VEGFR-2 inhibitor with IC50 of 3-60 nM for C-Raf/B-Raf/B-Raf V600E, EC50 of 30 nM for VEGFR2 phosphorylation; blocks Raf-MEK-ERK signalling and significantly enhances TRAIL sensitivity in NCI-H727 and CM insulinoma cells; inhibits cell proliferation with IC50 of 0.83-5.54 uM in CRC cells, demonstrates significant anti-tumor activity in tumors of xenograft models.Skin Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsCHIR-265 | RAF 265 | RAF-265 | CHIR265
-
PathwayMAPK/ERK Signaling
-
TargetRaf
-
RecptorB-Raf| VEGFR2
-
Research AreaCancer
-
IndicationSkin Cancer
Chemical Information
-
CAS Number927880-90-8
-
Formula Weight518.4139
-
Molecular FormulaC24H16F6N6O
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 26 mg/mL
-
SMILESFC(F)(C1=CN=C(N1)C2=NC=CC(OC3=CC=C4N(C(NC5=CC=C(C(F)(F)F)C=C5)=NC4=C3)C)=C2)F
-
Chemical Name1H-Benzimidazol-2-amine, 1-methyl-5-[[2-[5-(trifluoromethyl)-1H-imidazol-2-yl]-4-pyridinyl]oxy]-N-[4-(trifluoromethyl)phenyl]-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Mordant P, et al. Mol Cancer Ther. 2010 Feb;9(2):358-68.
2. Zitzmann K, et al. Endocr Relat Cancer. 2011 Mar 21;18(2):277-85.
3. Su Y, et al. Clin Cancer Res. 2012 Apr 15;18(8):2184-98.
4. Chen J, et al .Cancer Res. 2011 Jun 15;71(12):4280-91.
molnova catalog
related products
-
Lonafarnib
Lonafarnib is an orally bioavailable FPTase inhibitor for H-ras, K-ras-4B and N-ras with IC50 of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Phase 3.
-
Locostatin
Locostatin is a potent and cell permeable inhibitor of Raf kinase inhibitor protein (RKIP)/Raf1 kinase interaction and an inhibitor of cell migration.Locostatin treatment resulted in the activation of the mitogen-activated protein kinase (MAPK) signal pathway (ERK phosphorylation), providing a powerful validation of our targeting protocol.?
-
AZ304
AZ304 is a novel potent, dual BRAF inhibitor targeting the kinase domains of wild type BRAF, V600E mutant BRAF and wild type CRAF with IC50 of 79 nM, 38 nM and 68 nM, respectively.
